Publications by authors named "A Gurpide"
Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma.
EBioMedicine
April 2024
Article Synopsis
- Tobacco significantly increases the risk of lung cancer, but some heavy smokers either develop it early or remain illness-free for many years, indicating a variability in susceptibility to cancer.
- Researchers analyzed the genetic profiles of heavy smokers who either developed lung adenocarcinoma at a young age or did not develop it at an old age using Whole Exome Sequencing and Machine Learning to identify genetic variants linked to these extreme phenotypes.
- The study validated multiple genetic variants and found that the gene HLA-A had the most variants associated with lower lung cancer risk, achieving a notable prediction accuracy with machine learning models, suggesting potential pathways for further research into lung cancer prevention.
Article Synopsis
- The treatment landscape for metastatic urothelial carcinoma is evolving, with the combination of pembrolizumab and enfortumab vedotin emerging as a potentially better option than traditional platinum-based chemotherapies.
- New challenges arise regarding the best second-line treatments and the importance of molecular profiling of tumors in therapy selection.
- Recent trials have shown that combining nivolumab with platinum-based chemotherapy may be more effective than chemotherapy alone, highlighting the need for further translational research to understand these differing results.
Aims: Characterization of PSA in extracellular microvesicles (EVs) and its reactivity to commercial methods.
Materials And Methods: EVs derived from serum of 47 prostate cancer (PCa) patients, 27 benign prostatic hyperplasia (BPH) patients and 42 healthy controls were analyzed. EVs isolation and quantification of PSA immunoreactive to total (ev-T-PSA) or free (ev-F-PSA) PSA immunoassays, were performed using commercial assays.
Introduction: SCLC is an extremely aggressive subtype of lung cancer without approved targeted therapies. Here we identified YES1 as a novel targetable oncogene driving SCLC maintenance and metastasis.
Methods: Association between YES1 levels and prognosis was evaluated in SCLC clinical samples.
Background: To analyze the long-term outcomes for advanced cancer patients admitted to an intermediate care unit (ImCU), an analysis of a do not resuscitate orders (DNR) subgroup was made. Methods: A retrospective observational study was conducted from 2006 to January 2019 in a single academic medical center of cancer patients with stage IV disease who suffered acute severe complications. The Simplified Acute Physiology Score 3 (SAPS 3) was used as a prognostic and severity score.
View Article and Find Full Text PDF